Aclaris Therapeutics, Inc. (8AT.F)
| Previous Close | 1.0370 |
| Open | 1.0290 |
| Bid | 1.0510 x 0 |
| Ask | 1.0975 x 0 |
| Day's Range | 1.0290 - 1.0290 |
| 52 Week Range | 0.5900 - 5.2500 |
| Volume | |
| Avg. Volume | 153 |
| Market Cap | 75.703M |
| Beta (5Y Monthly) | 0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7500 |
| Earnings Date | Nov 04, 2024 - Nov 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.80 |
GuruFocus.comMillennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
On September 30, 2024, Millennium Management LLC, a prominent hedge fund, executed a significant transaction involving the shares of Aclaris Therapeutics Inc (NASDAQ:ACRS). The firm reduced its holdings by 331,252 shares, resulting in a new total of 3,005,598 shares in the biopharmaceutical company. This move reflects a strategic adjustment in Millenniums investment portfolio, with the shares priced at $1.15 during the transaction.
ZacksIs BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?
Here is how BellRing Brands (BRBR) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.
GlobeNewswireAclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris' Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase (JAK) 3, for the treatment of moderate to severe atopic dermatitis (AD). "We ar
